The California health system is working with Canexia to assess if a triaged, in-house testing strategy improves outcomes, lowers cost, and reduces access inequities.
March 11, 2021
If we are to minimize the now well-documented burdens of COVID-19 on cancer patients, governments must support innovations that improve their outcomes and cut through the healthcare roadblocks posed by the pandemic.
January 11, 2021
Canexia Health provides an update on Project ACTT and announces new partnerships.
December 3, 2020
In this exclusive interview, Dr. Huntsman discusses the elements of precision medicine that have contributed to its growth in oncology, some of the setbacks regarding its integration, and areas of research that have the potential to propel precision medicine to the next tier of scientific discovery and application.
September 16, 2020
Funding comes after the company meets key milestones with new collaborations and studies, product enhancements, and reimbursement progress.
July 15, 2020
A consortium led by Vancouver-based Canexia Health (formerly Contextual Genomics) will enable access to critical testing and treatment options for Canadian cancer patients during the COVID-19 pandemic.
January 17, 2020
Contextual Genomics and Eastern Ontario Regional Laboratory Association, a nonprofit organization offering high quality, patient focused, hospital-based lab services in Eastern Ontario, announced that they have partnered to bring Contextual Genomics’ ctDNA cancer genomic testing to EORLA’s Champlain Local Health Integration Network of Eastern Ontario, Canada.
January 13, 2020
Contextual Genomics and Lab Genomics, a personalized medicine company providing state of the art molecular genetic testing in Southern California, announced that they have signed an agreement enabling Lab Genomics to offer Contextual Genomics’ quality assured Next Generation Sequencing based ctDNA cancer genomic testing to patients in Southern California and other parts of the United States.
January 10, 2020
Contextual Genomics announced that it has named Brady Davis to its executive team. Mr. Davis, a veteran of the life sciences, healthcare and software industries, joins as Senior Vice President, Business Development of the Company, responsible for global strategy and business development.
Every Canexia Health report comes with therapeutic recommendations based on specific gene mutations and patient profiles, with clinical trials reviewed and selected by certified clinical molecular geneticists.